S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Home Depot Results Point To Sluggish 2nd Half
2 Long-Term EV Plays Trading Under $20
Are These 3 Video Game Stocks Now In Play?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
What's in big Biden bill? Health, climate goals become law
Biden to sign massive climate and health care legislation
Why Apple is Primed to Take a Bite Out of Live Sports
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Home Depot Results Point To Sluggish 2nd Half
2 Long-Term EV Plays Trading Under $20
Are These 3 Video Game Stocks Now In Play?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
What's in big Biden bill? Health, climate goals become law
Biden to sign massive climate and health care legislation
Why Apple is Primed to Take a Bite Out of Live Sports
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Home Depot Results Point To Sluggish 2nd Half
2 Long-Term EV Plays Trading Under $20
Are These 3 Video Game Stocks Now In Play?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
What's in big Biden bill? Health, climate goals become law
Biden to sign massive climate and health care legislation
Why Apple is Primed to Take a Bite Out of Live Sports
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Home Depot Results Point To Sluggish 2nd Half
2 Long-Term EV Plays Trading Under $20
Are These 3 Video Game Stocks Now In Play?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
What's in big Biden bill? Health, climate goals become law
Biden to sign massive climate and health care legislation
Why Apple is Primed to Take a Bite Out of Live Sports
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
NASDAQ:GRFS

Grifols - GRFS Stock Forecast, Price & News

$8.84
-0.08 (-0.90%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$8.79
$8.95
50-Day Range
$8.29
$12.86
52-Week Range
$8.28
$15.90
Volume
738,488 shs
Average Volume
1.02 million shs
Market Capitalization
$6.08 billion
P/E Ratio
7.37
Dividend Yield
N/A
Price Target
$15.77

Grifols MarketRank™ Forecast

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
78.4% Upside
$15.77 Price Target
Short Interest
Healthy
2.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.75mentions of Grifols in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
39.71%
From $0.68 to $0.95 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.60 out of 5 stars

Medical Sector

140th out of 1,122 stocks

Pharmaceutical Preparations Industry

53rd out of 551 stocks

GRFS stock logo

About Grifols (NASDAQ:GRFS) Stock

Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum-from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring-to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.

Grifols Price Performance

NASDAQ:GRFS traded down $0.08 during trading on Tuesday, reaching $8.84. The company's stock had a trading volume of 738,488 shares, compared to its average volume of 947,396. The business's fifty day moving average price is $10.73 and its 200-day moving average price is $11.31. Grifols has a twelve month low of $8.28 and a twelve month high of $15.90. The company has a current ratio of 2.68, a quick ratio of 0.91 and a debt-to-equity ratio of 1.20.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on GRFS shares. Berenberg Bank boosted their price objective on shares of Grifols from €20.15 ($20.56) to €20.30 ($20.71) and gave the stock a "buy" rating in a research report on Friday, July 15th. Jefferies Financial Group initiated coverage on shares of Grifols in a research note on Monday, July 25th. They issued a "hold" rating for the company. Finally, Deutsche Bank Aktiengesellschaft cut their target price on Grifols from €17.00 ($17.35) to €16.00 ($16.33) and set a "hold" rating on the stock in a research report on Tuesday, August 2nd. One analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $15.77.

Receive GRFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Grifols and its competitors with MarketBeat's FREE daily newsletter.

GRFS Stock News Headlines

Form 6-K Grifols SA For: Jun 30 - StreetInsider.com
See More Headlines
Receive GRFS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Grifols and its competitors with MarketBeat's FREE daily newsletter.

GRFS Company Calendar

Last Earnings
5/04/2021
Today
8/17/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GRFS
Employees
23,234
Year Founded
1909

Price Target and Rating

Average Stock Price Forecast
$15.77
High Stock Price Forecast
$20.30
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+78.4%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.84 billion
Cash Flow
$1.01 per share
Book Value
$13.03 per share

Miscellaneous

Free Float
N/A
Market Cap
$6.08 billion
Optionable
Optionable
Beta
0.28

Social Links


Key Executives

  • Mr. Raimon Grifols Roura (Age 58)
    Co-CEO & Exec. Director
    Comp: $906.57k
  • Mr. Víctor Grifols Deu (Age 45)
    Co-CEO & Exec. Director
    Comp: $906.57k
  • Mr. Alfredo Arroyo Guerra (Age 64)
    CFO & VP
  • Mrs. Eva Bastida Tubau
    Corp. VP and Director of Scientific & Medical Affairs
  • Ms. Nuria Pascual Lapeña (Age 58)
    VP of Corp. Treasury, Risk Management Investor Relation & Sustainability Officer
  • Mr. David Ian Bell (Age 68)
    Gen. Counsel & Chief Corp. Devel. Officer
  • Ms. Maria Teresa-Rioné Llano (Age 57)
    Chief Communications Officer
  • Mr. Mateo Florencio Borrás Humbert (Age 66)
    Corp. VP & Chief HR Officer
  • Ms. Montserrat Gaja Llamas (Age 57)
    Chief HR Officer
  • Mr. Francisco Javier Jorba Ribes (Age 71)
    Corp. VP and Pres of the Biological Industrial Group













GRFS Stock - Frequently Asked Questions

Should I buy or sell Grifols stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Grifols in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GRFS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRFS, but not buy additional shares or sell existing shares.
View GRFS analyst ratings
or view top-rated stocks.

What is Grifols' stock price forecast for 2022?

6 equities research analysts have issued twelve-month price targets for Grifols' stock. Their GRFS share price forecasts range from $11.00 to $20.30. On average, they predict the company's share price to reach $15.77 in the next twelve months. This suggests a possible upside of 78.4% from the stock's current price.
View analysts price targets for GRFS
or view top-rated stocks among Wall Street analysts.

How have GRFS shares performed in 2022?

Grifols' stock was trading at $11.23 at the beginning of the year. Since then, GRFS stock has decreased by 21.3% and is now trading at $8.84.
View the best growth stocks for 2022 here
.

How were Grifols' earnings last quarter?

Grifols, S.A. (NASDAQ:GRFS) issued its quarterly earnings data on Tuesday, May, 4th. The biotechnology company reported $0.21 EPS for the quarter, missing analysts' consensus estimates of $0.22 by $0.01. The biotechnology company had revenue of $1.43 billion for the quarter.

When did Grifols' stock split?

Grifols shares split before market open on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were distributed to shareholders after the closing bell on Thursday, December 31st 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What is Raimon Grifols and Victor Grifols Deu's approval rating as Grifols' CEO?

205 employees have rated Grifols Chief Executive Officer Raimon Grifols and Victor Grifols Deu on Glassdoor.com. Raimon Grifols and Victor Grifols Deu has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Grifols own?
What is Grifols' stock symbol?

Grifols trades on the NASDAQ under the ticker symbol "GRFS."

Who are Grifols' major shareholders?

Grifols' stock is owned by a number of institutional and retail investors. Top institutional investors include Black Creek Investment Management Inc. (1.01%), Pictet Asset Management SA (0.78%), State Street Corp (0.46%), JPMorgan Chase & Co. (0.45%), Soditic Asset Management LLP (0.15%) and SG Americas Securities LLC (0.15%).

How do I buy shares of Grifols?

Shares of GRFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Grifols' stock price today?

One share of GRFS stock can currently be purchased for approximately $8.84.

How much money does Grifols make?

Grifols (NASDAQ:GRFS) has a market capitalization of $6.08 billion and generates $5.84 billion in revenue each year.

How many employees does Grifols have?

The company employs 23,234 workers across the globe.

Does Grifols have any subsidiaries?
The following companies are subsidiares of Grifols: Aigües Minerals de Vilajuiga S.A., Araclon Biotech, Araclon Biotech S.L., Asociación I+D Progenika, Biomat S.A., Biomat USA Inc., Biotest Pharmaceutical Corporation, Biotest US Corporation, Chiquito Acquisition Corp., Diagnostic Grifols S.A., Goetech LLC (D/B/A Medkeeper), Gri-Cel S.A. , Grifols (H.K.) Limited, Grifols (Thailand) Ltd, Grifols Argentina S.A., Grifols Asia Pacific Pte Ltd, Grifols Australia Pty Ltd., Grifols Biologicals LLC., Grifols Brasil Lda., Grifols Canada Ltd., Grifols Chile S.A., Grifols Colombia Ltda, Grifols Deutschland GmbH, Grifols Diagnostics Equipment Taiwan Limited, Grifols Diagnostics Solutions Inc, Grifols Engineering S.A., Grifols France S.A.R.L., Grifols India Healthcare Private Ltd, Grifols Innovation and New Technologies Limited, Grifols International S.A., Grifols Italia S.p.A, Grifols Japan K.K., Grifols Malaysia Sdn Bhd, Grifols Movaco S.A., Grifols México S.A. de C.V., Grifols Nordic AB, Grifols Pharmaceutical Technology (Shanghai) Co. Ltd., Grifols Polska Sp.z.o.o., Grifols Portugal Productos Farmacéuticos e Hospitalares Lda., Grifols Shared Services North America Inc., Grifols Switzerland AG, Grifols Therapeutics LLC., Grifols UK Ltd., Grifols USA LLC., Grifols Viajes S.A., Grifols Worldwide Operations Limited, Grifols Worldwide Operations Spain S.A., Grifols Worldwide Operations USA Inc., Grifols s.r.o., Gripdan Invest S.L, Haema AG, Instituto Grifols S.A., Interstate Blood Bank Inc., Kiro Grifols S.L, Kiro Robotics, Laboratorios Grifols S.A., Logística Grifols S.A. de C.V., Medion Diagnostics GmbH, Medion Grifols Diagnostic AG, PBS Acquisition Corp., Progenika Biopharma, Progenika Biopharma S.A., Squadron Reinsurance Designated Activity Company, Talecris Biotherapeutics, Talecris Plasma Resources Inc., and VCN Bioscience S.L..
Read More
When was Grifols founded?

Grifols was founded in 1909.

How can I contact Grifols?

Grifols' mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The official website for the company is www.grifols.com. The biotechnology company can be reached via phone at (493) 571-2200, via email at inversores@grifols.com, or via fax at 34-93-571-0267.

This page (NASDAQ:GRFS) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.